U.S. pharmaceutical giant Gilead Sciences has announced plans to acquire Oxford University biotech spinout company MiroBio in an all-cash deal worth $405 million. MicroBio is a clinical-stage company focused on developing treatments to “restore immune balance” in autoimmune patients, which is when a person’s immune system attacks their own body tissues. Spearheaded by Professor Simon […]...